Categories Earnings, Health Care

ACADIA Pharmaceuticals (ACAD): Q3 2019 Earnings Snapshot

— ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) reported Q3 2019 loss of $0.29 per share, vs. $0.40 expected.

— Revenues grew 62% to $94.6 million, vs. $88.4 million expected.

— Research and development expenses were $62.6 million, compared to $53.1 million last year.

— FY19 NUPLAZID net sales guidance is increased to $330 million to $340 million from the previous range of $320 million to $330 million.

— ACAD shares fell 0.81% following the announcement.

Get access to timely and accurate verbatim transcripts that are published within hours of the event.

Most Popular

Micron Technology (MU) Q3 Earnings: Key financials and quarterly highlights

Micron Technology Inc. (NASDAQ: MU) reported third quarter 2022 earnings results today. Revenue increased 16% year-over-year to $8.64 billion. GAAP net income was $2.63 billion, or $2.34 per share, compared

Constellation Brands (STZ): Earnings beat and share structure revamp put brewer in the spotlight

Shares of Constellation Brands Inc. (NYSE: STZ) were down 4% on Thursday despite the company beating expectations on its first quarter 2023 earnings results. The stock has dropped 7% year-to-date.

Infographic: Key highlights from Constellation Brands (STZ) Q1 2023 earnings results

Constellation Brands, Inc. (NYSE: STZ) reported first quarter 2023 earnings results today. Net sales increased 17% year-over-year to $2.3 billion. Net income attributable to CBI was $390 million, or $2.06

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top